July 2026's Top Stock Selections Estimated Below Intrinsic Value
Over the last 7 days, the United States market has remained flat, yet it is up 17% over the past year with earnings expected to grow by 17% per annum over the next few years. In this environment, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Tutor Perini (TPC) | $83.28 | $163.76 | 49.1% |
| Reddit (RDDT) | $178.04 | $354.88 | 49.8% |
| Rayonier (RYN) | $21.39 | $42.36 | 49.5% |
| Ouster (OUST) | $35.53 | $68.77 | 48.3% |
| Luckin Coffee (LKNC.Y) | $33.30 | $65.59 | 49.2% |
| Huntington Bancshares (HBAN) | $17.08 | $32.98 | 48.2% |
| HBT Financial (HBT) | $35.86 | $69.21 | 48.2% |
| Genuine Parts (GPC) | $124.83 | $244.79 | 49% |
| FatPipe (FATN) | $5.12 | $9.97 | 48.6% |
| Dime Commercial Bancshares (DCOM) | $40.80 | $79.24 | 48.5% |
Let's review some notable picks from our screened stocks.
Nutanix (NTNX)
Overview: Nutanix, Inc. offers an enterprise cloud platform across various regions including North America, Europe, the Asia Pacific, the Middle East, Latin America, and Africa with a market cap of approximately $16.10 billion.
Operations: The company's revenue primarily comes from its Internet Software & Services segment, generating approximately $2.75 billion.
Estimated Discount To Fair Value: 27.4%
Nutanix is trading at US$59.26, below its estimated future cash flow value of US$81.64, suggesting it is undervalued based on cash flows. Despite high debt levels and recent index removals, Nutanix's earnings are projected to grow significantly at 25.1% annually, outpacing the broader US market. Recent strategic moves in edge computing with GigaIO enhance its technological capabilities and market appeal, potentially supporting future financial performance despite insider selling concerns.
- Our earnings growth report unveils the potential for significant increases in Nutanix's future results.
- Click to explore a detailed breakdown of our findings in Nutanix's balance sheet health report.
KKR (KKR)
Overview: KKR & Co. Inc. is a private equity and real estate investment firm specializing in direct and fund of fund investments, with a market cap of approximately $89.13 billion.
Operations: KKR's revenue segments include Private Markets generating $5.67 billion and Public Markets contributing $1.34 billion.
Estimated Discount To Fair Value: 15.2%
KKR's current trading price of US$100.98 falls below its estimated future cash flow value of US$119.02, indicating potential undervaluation based on cash flows. Earnings are projected to grow significantly at 26.1% annually, surpassing the broader US market growth rate. Recent earnings reports show substantial net income increases, and strategic ventures like the joint venture with Kuwait Oil Company could bolster long-term revenue streams despite a forecasted low return on equity in three years.
- Our expertly prepared growth report on KKR implies its future financial outlook may be stronger than recent results.
- Click here and access our complete balance sheet health report to understand the dynamics of KKR.
Teva Pharmaceutical Industries (TEVA)
Overview: Teva Pharmaceutical Industries Limited is involved in the development, manufacturing, marketing, and distribution of generic and biopharmaceutical products across the United States, Europe, Israel, and other international markets with a market cap of $40.45 billion.
Operations: Teva generates revenue through its operations in the development, production, and sale of generic medicines and biopharmaceutical products across various regions including the United States, Europe, Israel, and other international markets.
Estimated Discount To Fair Value: 44.6%
Teva Pharmaceutical Industries, trading at US$35.41, is significantly undervalued compared to its estimated future cash flow value of US$63.96. Despite a recent net loss in Q2 2026, Teva's earnings are forecasted to grow substantially at 28.8% annually over the next three years, outpacing the broader market growth rate. The company has raised its revenue guidance for 2026 due to strong performance in key products like AUSTEDO and AJOVY, indicating robust cash flow potential despite current financial challenges.
- Insights from our recent growth report point to a promising forecast for Teva Pharmaceutical Industries' business outlook.
- Delve into the full analysis health report here for a deeper understanding of Teva Pharmaceutical Industries.
Where To Now?
- Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 161 companies by clicking here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com